Filana Therapeutics, Inc. (FLNA) - Total Liabilities
Based on the latest financial reports, Filana Therapeutics, Inc. (FLNA) has total liabilities worth $43.95 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Filana Therapeutics, Inc. cash conversion from operations to assess how effectively this company generates cash.
Filana Therapeutics, Inc. - Total Liabilities Trend (2022–2025)
This chart illustrates how Filana Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. See FLNA net assets for net asset value and shareholders' equity analysis.
Filana Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of Filana Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ANDRADA MINING LTD.
F:9IA
|
Germany | €43.56 Million |
|
Falcon Metals Ltd
AU:FAL
|
Australia | AU$883.21K |
|
Abeo SAS
PA:ABEO
|
France | €231.07 Million |
|
SAMRYOONG Co.Ltd
KQ:014970
|
Korea | ₩41.95 Billion |
|
Bilici Yatirim Sanayi ve Ticaret AS
IS:BLCYT
|
Turkey | TL910.61 Million |
|
DCM Corp
KO:024090
|
Korea | ₩31.58 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down Filana Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Filana Therapeutics, Inc. market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.59 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Filana Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Filana Therapeutics, Inc. (2022–2025)
The table below shows the annual total liabilities of Filana Therapeutics, Inc. from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $43.95 Million | +271.56% |
| 2024-12-31 | $11.83 Million | -16.67% |
| 2023-12-31 | $14.20 Million | +94.59% |
| 2022-12-31 | $7.29 Million | -- |
About Filana Therapeutics, Inc.
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from… Read more